Join the Cancer group to help and get support from people like you.
Cancer News (Page 20)
Related terms: Carcinoma, Malignant Disease, Malignant Tumor
FDA Grants Accelerated Approval to Lartruvo (olaratumab) for Advanced Soft Tissue Sarcoma
October 19, 2016 – The U.S. Food and Drug Administration today granted accelerated approval to Lartruvo (olaratumab) with doxorubicin to treat adults with certain types of soft tissue sarcoma (STS),...
FDA Approves Merck’s Keytruda (pembrolizumab) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
KENILWORTH, N.J.--(BUSINESS WIRE)--August 5, 2016 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved...
FDA Approves Tecentriq (atezolizumab) for Urothelial Carcinoma
May 18, 2016 – The U.S. Food and Drug Administration today approved Tecentriq (atezolizumab) to treat the most common type of bladder cancer, called urothelial carcinoma. This is the first product...
FDA Medwatch Alert: Adrucil (fluorouracil injection, USP) 5 g/100 mL (50 mg/mL) by Teva Parenteral Medicines: Recall - Particulate Matter
[Posted 07/27/2015] ISSUE: Teva Parenteral Medicines announced a voluntary recall of six lots of Adrucil (fluorouracil injection, USP) 5 g/100 mL (50 mg/mL) due to the potential presence of...
FDA Medwatch Alert: Adrucil (fluorouracil Injection, USP) 5 g/100 mL (50 mg/mL): Recall - Particulate Matter
ISSUE: Teva Parenteral Medicines issued a voluntary recall of eight lots of Adrucil (fluorouracil injection, USP) 5 g/100 mL (50 mg/mL) due to the potential presence of particulate matter identified...
FDA Medwatch Alert: Injectable Products by Mylan: Recall - Presence of Particulate Matter
including certain lots of: Gemcitabine for Injection Carboplatin Injection Methotrexate Injection Cytarabine Injection See the press release for a listing of the product strength, NDC, and lot...
FDA Approves Cyramza (Ramucirumab) for Use with FOLFIRI in Second-Line Treatment of Metastatic Colorectal Cancer
INDIANAPOLIS, April 24, 2015 /PRNewswire/ – Eli Lilly and Company (NYSE: LLY) has received its fourth U.S. Food and Drug Administration (FDA) approval for Cyramza (ramucirumab). Cyramza (ramucirumab...
FDA Approves Akynzeo (netupitant and palonosetron) for Chemotherapy-Induced Nausea and Vomiting
October 10, 2014 – The U.S. Food and Drug Administration today approved Akynzeo (netupitant and palonosetron) to treat nausea and vomiting in patients undergoing cancer chemotherapy. Akynzeo is a...
FDA Medwatch Alert: Docetaxel: Drug Safety Communication - May Cause Symptoms of Alcohol Intoxication
ISSUE: FDA is warning that the intravenous chemotherapy drug docetaxel contains ethanol, also known as alcohol, which may cause patients to experience intoxication or feel drunk during and after...
FDA Medwatch Alert: Methotrexate Sodium, USP Injectable Vials by Sandoz US: Recall - Particulate Matter In Vials
ISSUE: Sandoz is conducting a voluntary nationwide recall to the hospital/user level of two lots of its Methotrexate Sodium, USP, 25 mg/mL, 40 mL vial injectable product in the US, due to the...
FDA Approves Lymphoseek to Help Locate Lymph Nodes in Patients with Certain Cancers
March 13, 2013 – The U.S. Food and Drug Administration today approved Lymphoseek (technetium Tc 99m tilmanocept) Injection, a radioactive diagnostic imaging agent that helps doctors locate lymph...
FDA Medwatch Alert: Hospira Injectable Drug Products: Recall - Visible Particulates from Defective Glass Vials
Including certain lots of the following products: carboplatin cytarabine paclitaxel methotrexate [Posted 07/16/2012] ISSUE: Hospira and FDA notified healthcare professional of a nationwide recall...
Further information
Related condition support groups
Breast Cancer, Prostate Cancer, Colorectal Cancer, Renal Cell Carcinoma, Skin Cancer, Ovarian Cancer, Endometrial Cancer, Lung Cancer, Gastric Cancer